Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mocroft

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
AIDS Research and Human Retroviruses|July 2, 2005
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfectionA Mocroft, A N Phillips, V Soriano, et al.
HIV Medicine|October 15, 2013
A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infectionA Mocroft, L Ryom, P Reiss, et al.
AIDS (London, England)|June 17, 1999
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study groupA Mocroft, O Kirk, S E Barton, et al.
Lancet (London, England)|July 11, 2003
Decline in the AIDS and death rates in the EuroSIDA study: an observational studyA Mocroft, B Ledergerber, C Katlama, et al.
HIV Medicine|January 18, 2008
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999A Mocroft, A Horban, B Clotet, et al.
HIV Medicine|March 29, 2013
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapyD Grint, L Peters, J Reekie, et al.
AIDS Research and Human Retroviruses|October 13, 2005
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfectionA Mocroft, A N Phillips, V Soriano, et al.
HIV Medicine|March 14, 2007
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or deathC Holkmann Olsen, A Mocroft, O Kirk, et al.
HIV Medicine|February 19, 2016
Infection-related and -unrelated malignancies, HIV and the aging populationL Shepherd, Áh Borges, B Ledergerber, et al.
AIDS (London, England)|June 16, 2001
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavirO Kirk, A Mocroft, C Pradier, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
AIDS Research and Human Retroviruses|July 2, 2005
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfectionA Mocroft, A N Phillips, V Soriano, et al.
HIV Medicine|October 15, 2013
A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infectionA Mocroft, L Ryom, P Reiss, et al.
AIDS (London, England)|June 17, 1999
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study groupA Mocroft, O Kirk, S E Barton, et al.
Lancet (London, England)|July 11, 2003
Decline in the AIDS and death rates in the EuroSIDA study: an observational studyA Mocroft, B Ledergerber, C Katlama, et al.
HIV Medicine|January 18, 2008
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999A Mocroft, A Horban, B Clotet, et al.
HIV Medicine|March 29, 2013
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapyD Grint, L Peters, J Reekie, et al.
AIDS Research and Human Retroviruses|October 13, 2005
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfectionA Mocroft, A N Phillips, V Soriano, et al.
HIV Medicine|March 14, 2007
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or deathC Holkmann Olsen, A Mocroft, O Kirk, et al.
HIV Medicine|February 19, 2016
Infection-related and -unrelated malignancies, HIV and the aging populationL Shepherd, Áh Borges, B Ledergerber, et al.
AIDS (London, England)|June 16, 2001
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavirO Kirk, A Mocroft, C Pradier, et al.
Pageof 12